HUAWEI is strengthening its contributions to cardiovascular health research, with studies involving its wearable devices gaining recognition at two international medical conferences: the 19th Asia Pacific Heart Rhythm Society (APHRS) Scientific Session in South Korea and the 31st International Society of Hypertension Scientific Meeting and 17th Emirates Cardiac Society Annual Conference (ISH-ECS) in Dubai.
At ISH-ECS 2026, HUAWEI also presented its latest blood pressure monitoring innovations, including the HUAWEI WATCH D3, and highlighted its collaboration with the International Society of Hypertension (ISH) through the newly established Wearable Blood Pressure Technology Innovation Fund.
Together, these developments reflect HUAWEI’s continued efforts to bridge medical research and consumer technology, bringing advanced cardiovascular monitoring capabilities closer to everyday users. Through devices such as the HUAWEI WATCH GT 7 Pro and WATCH D3, the company aims to make heart health and blood pressure monitoring more accessible while encouraging greater awareness of cardiovascular health.
Advancing Research Through Wearable Technology
At APHRS 2026, research involving HUAWEI wearable devices was cited in the 2026 Asia Pacific Atrial Fibrillation Guidelines. The recognition highlights the potential of wearable technology in clinical settings and the growing role of smart devices in supporting proactive heart health monitoring.
The study examined the links between sleep apnea, arrhythmia, blood pressure, and cardiovascular events using data from HUAWEI devices. Its findings demonstrate how wearable technology can contribute to further cardiovascular research.¹
Advancing Blood Pressure Monitoring Through Global Research
At ISH-ECS 2026, HUAWEI showcased its latest developments in blood pressure monitoring through its collaboration with ISH and the Wearable Blood Pressure Technology Innovation Fund.
The company introduced its Minimally Disruptive Ambulatory Blood Pressure Monitoring (ABPM) research initiative at the conference. Developed in partnership with Ruijin Hospital, the study explores a hybrid approach that combines continuous photoplethysmography (PPG) monitoring with airbag-based blood pressure measurements. The approach aims to reduce reliance on cuff-based readings, potentially making long-term blood pressure monitoring more comfortable and practical.
“Innovations like Minimally Disruptive ABPM and environmental monitoring reminders by HUAWEI Watch D3 may be inspiring for shaping a new direction on how future blood pressure management is automated and seamlessly embedded into daily life, via wearable devices,” said Professor Wang Jiguang, President of the Chinese Hypertension Association.
HUAWEI WATCH D3 and GT 7 Series: Advanced, All-in-One Health Tracking
The HUAWEI WATCH D3 and GT 7 Pro feature a one-tap Health Glance assessment that analyzes key indicators, including heart rate, heart rate variability (HRV), blood oxygen levels, arterial elasticity, and ECG data, in seconds.
By combining these measurements, the watches generate a comprehensive report designed to help users better understand their health indicators and identify potential risks that may warrant further attention.
From early risk awareness to continuous long-term health management, HUAWEI continues to explore how smart technology can support greater health awareness. Through ongoing collaborations with global medical and research partners, the company aims to advance digital health solutions and make cardiovascular monitoring more accessible.
To learn more, visit HUAWEI’s official website or follow its social media accounts on Facebook and Instagram.
¹ Research findings are based on the specific study population and methodology and should not be interpreted as establishing causation or guaranteeing individual health outcomes.
² Product features and availability may vary by country or region. Please refer to local product specifications for details.